Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT

Anticancer Research

Volumn 29, Issue 11, 2009, Pages 4845-4854

  Fukushima, Tsuyoshi ^a   Takeshima, Hideo ^a   Kataoka, Hiroaki ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

Glioblastoma; O6 methylguanine DNA methyltransferase (MGMT); Review; Temozolomide

Indexed keywords

6 O BENZYLGUANINE; ANTINEOPLASTIC AGENT; BETA INTERFERON; BEVACIZUMAB; CARMUSTINE; CELECOXIB; CISPLATIN; ERLOTINIB; FOTEMUSTINE; HYDROXYUREA; IMATINIB; IRINOTECAN; LOMUSTINE; MARIMASTAT; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MITOZOLOMIDE; NIMUSTINE; PROCARBAZINE; PROTEIN P53; TEMOZOLOMIDE; TENIPOSIDE; THALIDOMIDE; VINCRISTINE;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURGERY; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DNA METHYLATION; DRUG MECHANISM; DRUG TRANSFORMATION; GENE EXPRESSION PROFILING; GENE SILENCING; GLIOBLASTOMA; GLIOMA; GLIOMA CELL; HUMAN; MELANOMA; MONOTHERAPY; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; TUMOR RECURRENCE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DNA REPAIR; GLIOBLASTOMA; HUMANS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE;

EID: 75149190139     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (105)

1. Kleihues P, Louis DN, Wiestier OD, Burger PC and Scheithauer: WHO grading of tumours of the central nervous system. In: WHO Classification of Tumours of the Central Nervous System, 4th Edition. Louis DN, Ohgaki H and Wiestler OD (eds.). Lyon, International Agency for Research on Cancer, pp. 10-11, 2007.
2. Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL abd Wilson CB: Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. J Rad One Biol Phys 18: 321-324,1990.
3. Stupp R, Mason WP, van den Bent MJ, Weiler M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
4. Friedman HS, Kerby T and Calvert H: Temozolomide and treatment of malignant glioma. Clin Cancer Res 6: 2585-2597, 2000.
5. 6-methylguanine-DNA methyltransferase and chloroethylnitrosourea- treated DNA. Cancer Res 52: 6052-6058, 1992.
6. 6-Methylguanine-DNA methyltransferase activity in breast and brain tumors. Int J Cancer 61: 321-326, 1995.
7. 6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. Clin Cancer Res 2: 735-741, 1996.
8. Estellar M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB and Herman JG: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343: 1350-1354, 2000.
9. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC and Stupp R: MGMT gene silencing and benefit from temozolo-mide in glioblastoma. N Engl J Med 352: 997-1003, 2005.
10. Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L, García-Lopez JL, Piquer J, Safont MJ, Balaũa C, Sanchez-Cespedes M, García-Villanueva M, Arribas L and Esteller M: CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10: 4933-4938, 2004.
11. 6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10: 1871-1874, 2004.
12. 6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis. Am J Surg Pathol 32: 1220-1227, 2008.
13. Stevens MF, Hickman JA, Stone R, Gibson NW, Baig GU, Lunt E and Newton CG: Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent. J Med Chem 27: 196-201, 1984.
14. Newlands ES, Blackledge G, Slack JA, Goddard C, Brindley CJ, Holden L and Stevens MF: Phase I clinical trial of mitozolomide. Cancer Treat Rep 69: 801-805, 1985.
15. Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson NW, Slack JA, Newton C, Lunt E, Fizames C and Lavelle F: Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl- imidazo[5,1-d]-1,23,5-tetrazin-4(3H)-one (CCRG 81045; M&B 39831), a novel drag with potential as an alternative to dacarbazine. Cancer Res 47: 5846-5852, 1987.
16. Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, Quarterman CP, Hoffman R, Stevens MF, Brampton MH and Gibson AC: Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65: 287-291, 1992.
17. Clark AS, Deans B, Stevens MF, Tisdale MJ, Wheelhouse RT, Denny BJ and Hartley JA: Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drag temozolomide. J Med Chem 38: 1493-1504,1995.
18. Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL and Slack JA: NMR and molecular modeling investigation of the mechanism of activation of the antitumor drag temozolomide and its interaction with DNA. Biochemistry 33: 9045-9051, 1994.
19. 6-Methylguanine-DNA methyltransferase inactivation and chemotherapy. Br Med Bull 85: 17-33, 2008.
20. 6-alkylguanine. Proc Natl Acad Sci USA 87: 686-690, 1990
21. 6- methylguanine-DNA methyltransferase gene in cultured human tumor cells. Mutat Res 273: 221-230, 1992.
22. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59: 793-797, 1999.
23. Day RS III, Ziolkowski CH, Scudiero DA, Meyer SA, Lubiniecki AS, Girardi AJ, Galloway SM and Bynum GD: Defective repair of alkylated DNA by human tumor and SV40-transformed human cell strains. Nature 288: 724-727, 1980.
24. - human tumor cells. Cancer Res 50: 7908-7911, 1990.
25. - human tumor cell lines containing the MGMT gene by the polymerase chain reaction technique. Cancer Commun 2: 13-20, 1990.
26. - human tumor cell lines. Carcinogenesis 16: 2255-2257, 1995.
27. 6- methylguanine-DNA methyltransferase gene correlates with MGMT expression in human glioma cells. Cancer Res 56: 13916-13924, 1996.
28. 6-methylguanine-DNA methyltransferase gene. Cancer Res 57: 3672-3677, 1997.
29. 6-Methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol 17: 5612-5619, 1997.
30. 6-methylguanine DNA methyltransferase in human cancer. Oncogene 23: 1-8, 2004.
31. 6-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res 61: 4689-4692, 2001.
32. Nakamura M, Watanabe T, Yonekawa Y, Kleihues P and Ohgaki H: Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C→A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 22: 1715-1719, 2001.
33. Wolf P, Hu YC, Doffek K, Sidransky D and Ahrendt SA: O(6)- Methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer. Cancer Res 61: 8113-8117, 2001.
34. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 60: 2368-2371, 2000.
35. Park TJ, Han SU, Cho YK, Paik WK, Kim YB and Lim IK: Methylation of O(6)-methylguanine-DNA methyltransferase gene is associated significantly with K-ras mutation, lymph node invasion, tumor staging, and disease-free survival in patients with gastric carcinoma. Cancer 92: 2760-2768, 2001.
36. 6methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 18: 520-532, 2008.
37. Mineura K, Yanagisawa T, Watanabe K, Kowada M and Yasui N: Human brain tumor O(6)-methylguanine-DNA methyltransferase mRNA and its significance as an indicator of selective chloroethylnitrosourea chemotherapy. Int J Cancer 69: 420-425, 1996.
38. 6-Methylguanine-DNA methyltransferase gene expression in gliomas by means of real-time quantitative RT-PCR and clinical response to nitrosoureas. Int J Cancer 103: 67-72, 2003.
39. 6-Benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. Cancer Res 59: 2402-2410, 1999.
40. 6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26: 4189-4199, 2008.
41. Rodriguez FJ, Thibodeau SN, Jenkins RB, Schowalter KV, Caron BL, O'Neill BP, James CD, Passe S, Slezak J and Giannini C: MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl Immunohistochem Mol Morphol 16: 59-65, 2008.
42. Burton EC and Prados MD: Malignant gliomas. Curr Treat Options Oncol 1: 459-468, 2000.
43. Chamberlain MC and Kormanik PA: Practical guidelines for the treatment of malignant gliomas. West J Med 168: 114-120, 1998.
44. Ammirati M, Vick N, Liao YL, Ciric I and Mikhael M: Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery 21: 201-206, 1987.
45. Pichlmeier U, Bink A, Schackert G and Stummer W; ALA Glioma Study Group: Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. Neuro Oncol 10: 1025-1034, 2008.
46. Yoshikawa K, Kajiwara K, Morioka J, Fujii M, Tanaka N, Fujisawa H, Kato S, Nomura S and Suzuki M: Improvement of functional outcome after radical surgery in glioblastoma patients: the efficacy of a navigation-guided fence-post procedure and neurophysiological monitoring. J Neurooncol 78: 91-97, 2006.
47. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA and Strike TA: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49: 333-343, 1978.
48. Walker MD, Strike TA and Sheline GE: An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 5: 1725-31, 1979.
49. Nieder C, Andratschke N, Wiedenmann N, Busch R, Grosu AL and Molls M: Radiotherapy for high-grade gliomas. Does altered fractionation improve the outcome? Strahlenther Onkol 180: 401-407, 2004.
50. Baumert BG, Brada M, Bernier J, Kortmann RD, Dehing-Oberije C, Collette L and Davis JB: EORTC 22972-26991/MRC BRIO trial: fractionated stereotactic boost following conventional radiotherapy of high grade gliomas. Clinical and quality-assurance results of the stereotactic boost arm. Radiother Oncol 88: 163-172, 2008.
51. Tsao MN, Mehta MP, Whelan TJ, Morris DE, Hayman JA, Flickinger JC, Mills M, Rogers CL and Souhami L: The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. Int J Radiat Oncol Biol Phys 63: 47-55, 2005.
52. Newton HB, Junck L, Bromberg J, Page MA and Greenberg HS: Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurology 40: 1743-1746, 1990.
53. Shapiro WR, Green SB, Burger PC, Selker RG, VanGilder JC, Robertson JT, Mealey J Jr, Ransohff J and Mahaley MS Jr: A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 76: 772-781, 1992..
54. Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL and Wilson CB: Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18: 321-324, 1990.
55. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA and Louis DN: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst (Bethesda) 90: 1473-1479, 1998.
56. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW and Jenkins RB: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18: 636-645, 2000.
57. Beppu T, Kamada K, Nakamura R, Oikawa H, Takeda M, Fukuda T, Arai H, Ogasawara K and Ogawa A: A phase II study of radiotherapy after hyperbaric oxygenation combined with interferon-beta and nimustine hydrochloride to treat supratentorial malignant gliomas. J Neurooncol 61: 161-170, 2003.
58. Watanabe T, Katayama Y, Yoshino A, Fukaya C and Yamamoto T: Human interferon beta, nimustine hydrochloride, and radiation therapy in the treatment of newly diagnosed malignant astrocytomas. J Neurooncol 72: 57-62, 2005.
59. Buckner JC, Ballman KV, Michalak JC, Burton GV, Cascino TL, Schomberg PJ, Hawkins RB, Scheithauer BW, Sandler HM, Marks RS and O' Fallon JR; North Central Cancer Treatment Group 93-72-52; Southwest Oncology Group 9503 Trials: Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials. J Clin Oncol 24: 3871-3879, 2006.
60. Smith KA, Ashby LS, Gonzalez F, Brachman DG, Thomas T, Coons SW, Battaglia M and Scheck A: Prospective trial of gross-total resection with Gliadel wafers followed by early postoperative gamma knife radiosurgery and conformai fractionated radiotherapy as the initial treatment for patients with radiographically suspected, newly diagnosed glioblastoma multiforme. J Neurosurg 109 Suppl: 106-117, 2008.
61. Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M, Fedoroff A, Sneed PK, Berger MS, McDermott MW, Parsa AT, Vandenberg S, James CD, Lamborn KR, Stokoe D and Haas-Kogan DA: Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma J Clin Oncol 27: 579-584, 2009.
62. McGirt MJ, Than KD, Weingart JD, Chaichana KL, Attenello FJ, Olivi A, Laterra J, Kleinberg LR, Grossman SA, Brem H and Quiñones-Hinojosa A: Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 110: 583-588, 2009.
63. Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, Geoffroy FJ, Arusell R, Kitange G, Jenkins RB, Kugler JW, Morton RF, Rowland KM Jr, Mischel P, Yong WH, Scheithauer BW, Schiff D, Giannini C and Buckner JC; North Central Cancer Treatment Group Study N0177: Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 26: 5603-5609, 2008.
64. Narayana A, Golfinos JG, Fischer I, Raza S, Kelly P, Parker E, Knopp EA, Medabalmi P, Zagzag D, Eagan P and Graber ML: Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys 72: 383-9, 2008.
65. Minniti G, De Sanctis V, Muni R, Rasio D, Lanzetta G, Bozzao A, Osti MF, Salvati M, Valeriani M, Cantore GP, Maurizi Enrici R: Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. J Neurooncol 91: 95-100, 2009.
66. Kesari S, Schiff D, Henson JW, Muzikansky A, Gigas DC, Doherty L, Batchelor TT, Longtine JA, Ligon KL, Weaver S, Laforme A, Ramakrishna N, Black PM, Drappatz J, Ciampa A, Folkman J, Kieran M and Wen PY: Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol 10: 300-308, 2008.
67. 6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol 25: 1470-1475, 2007.
68. Fountzilas G, Karkavelas G, Kalogera-Fountzila A, Karina M, Ignatiadis M, Koukoulis G, Plataniotis G, Misailidou D, Bobos M, Pectasides D, Razis E, Karavelis A and Selviaridis P: Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation. Anticancer Res 26: 4675-4686, 2006.
69. Colman H, Berkey BA, Maor MH, Groves MD, Schultz CJ, Vermeulen S, Nelson DF, Mehta MP and Yung WK; Radiation Therapy Oncology Group: Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710. Int J Radiat Oncol Biol Phys 66: 818-824, 2006.
70. 6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol 27: 1262-1267, 2009.
71. Wick A, Pascher C, Wick W, Jauch T, Weller M, Bogdahn U and Hau P: Rechallenge with temozolomide in patients with recurrent gliomas. J Neurol 256: 734-741, 2009.
72. Glas M, Hundsberger T, Stuplich M, Wiewrodt D, Kurzwelly D, Nguyen-Huu B, Rasch K and Herrlinger U: Nimustine (ACNU) plus teniposide (VM26) in recurrent glioblastoma. Oncology 76: 184-189, 2009.
73. van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, Carpentier AF, Clement PM, Frenay M, Campone M, Baurain JF, Armand JP, Taphoorn MJ, Tosoni A, Kletzl H, Klughammer B, Lacombe D and Gorlia T: Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 27: 1268-1274, 2009.
74. Brandes AA, Tosoni A, Franceschi E, Blatt V, Santoro A, Faedi M, Amistà P, Gardiman M, Labianca R, Bianchini C, Ermani M and Reni M: Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol, in press (DOI: 10.1007/s00280-009-0926-8)
75. Fabrini MG, Silvano G, Lolli I, Perrone F, Marsella A, Scotti V and Cionini L: A multi-institutional phase II study on second-line fotemustine chemotherapy in recurrent glioblastoma. J Neurooncol 92: 79-86, 2009.
76. Chamberlain MC and Johnston S: Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. J Neurooncol 91: 359-367, 2009.
77. Butowski N, Lamborn KR, Lee BL, Prados MD, Cloughesy T, Deangelis LM, Abrey L, Fink K, Lieberman F, Mehta M, Ian Robins H, Junck L, Salazar AM and Chang SM: A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol 91: 183-189, 2009.
78. Balmaceda C, Peereboom D, Pannullo S, Cheung YK, Fisher PG, Alavi J, Sisti M, Chen J, Fine RL. Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer 112: 1139-1146, 2008.
79. Silvani A, Lamperti E, Gaviani P, Eoli M, Fiumani A, Salmaggi A, Falcone C, Filippini G, Botturi A and Boiardi A: Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide-treated recurrent glioblastoma patients. J Neurooncol 87: 143-151, 2008.
80. Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E, Biscuola M, Blatt V, Crinò L and Ermani M; GICNO: Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from Grappo Italiano Cooperativo di Neuro-oncologia (GICNO). Br J Cancer 95: 1155-1160, 2006.
81. Groves MD, Puduvalli VK, Conrad CA, Gilbert MR, Yung WK, Jaeckle K, Liu V, Hess KR, Aldape KD and Levin VA: Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. J Neurooncol 80: 83-90, 2006.
82. Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gurarangan S, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE 2nd, Dowell JM, Badraddoja MA, McLendon RE, Lagattuta TF, Kicielinski KP, Dresemann G, Sampson JH, Friedman AH, Salvado AJ and Friedman HS: Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 23: 9359-9368, 2005.
83. Prados MD, Yung WK, Fine HA, Greenberg HS, Junck L, Chang SM, Nicholas MK, Robins HI, Mehta MP, Fink KL, Jaeckle KA, Kuhn J, Hess KR and Schold SC Jr; North American Brain Tumor Consortium study: Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. Neuro Oncol 6: 33-37, 2004.
84. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schüler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lütolf UM and Kleihues P: Genetic pathways to glioblastoma: a population-based study. Cancer Res 64: 6892-6899, 2004.
85. Plowman J, Waud WR, Koutsoukos AD, Rubinstein LV, Moore TD and Grever MR: Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1- nitrosourea. Cancer Res 54: 3793-3799, 1994.
86. Friedman HS, Johnson SP, Dong Q, Schold SC, Rasheed BK, Bigner SH, Ali-Osman F, Dolan E, Colvin OM, Houghton P, Germain G, Drummond JT, Keir S, Marcelli S, Bigner DD and Modrich P: Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res 57: 2933-2936, 1997.
87. Liu L, Markowitz S and Gerson SL: Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res 56: 5375-5379, 1996.
88. Liu L, Taverna P, Whitacre CM, Chatterjee S and Gerson SL: Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clin Cancer Res 5: 2908-2917, 1999.
89. Tentori L, Portarena I, Torino F, Scerrati M, Navarra P and Graziani G: Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells. Glia 40: 44-54, 2002.
90. Curtin NJ, Wang LZ, Yiakouvaki A, Kyle S, Arris CA, Canan-Koch S, Webber SE, Durkacz BW, Calvert HA, Hostomsky Z and Newell DR: Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin Cancer Res 10: 881-889, 2004
91. Dungey FA, Löser DA and Chalmers AJ: Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys 72: 1188-1197, 2008.
92. Tentori L, Leonetti C, Scarsella M, d'Amati G, Portarena I, Zupi G, Bonmassar E and Graziani G: Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood 99: 2241-2224, 2002.
93. Clarke MJ, Mulligan EA, Grogan PT, Mladek AC, Carlson BL, Schroeder MA, Curtin NJ, Lou Z, Decker PA, Wu W, Plummer ER and Sarkaria JN: Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Mol Cancer Ther 8: 407-414, 2009.
94. Milano V, Piao Y, LaFortune T and de Groot J: Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma. Mol Cancer Ther 8: 394-406, 2009.
95. de Oliveira MS, Cechim G, Braganhol E, Santos DG, Meurer L, de Castro CG Jr, Brunetto AL, Schwarstmann G, Battastini AM, Lenz G and Roesler R: Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models. J Neurooncol 93: 191-201, 2009
96. 6-methylguanine-DNA methyltransferase in human melanoma cells. MoI Cancer Ther 7: 3842-3851, 2008.
97. Lu C and Shervington A: Chemoresistance in gliomas. Mol Cell Biochem 312: 71-80, 2008.
98. Singh SK, Clarke ID, Hide T and Dirks PB: Cancer stem cells in nervous system tumors. Oncogene 23: 7267-7273, 2004.
99. Schaich M, Kestel L, Pfirrmann M, Robel K, Illmer T, Kramer M, Dill C, Ehninger G, Schackert G and Krex D: A MDRl (ABCBl) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann Oncol 20: 175-181, 2009.
100. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven MC, Hainfellner JA, Heppner FL, Dietrich PY, Zimmer Y, Cairncross JG, Janzer RC, Domany E, Delorenzi M, Stupp R and Hegi ME: Stem cell-related 'self-renewal' signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 26: 3015-3024, 2008.
101. Beier D, Röhrl S, Pillai DR, Schwarz S, Kunz-Schughart LA, Leukel P, Proescholdt M, Brawanski A, Bogdahn U, Trampe-Kieslich A, Giebel B, Wischhusen J, Reifenberger G, Hau P and Beier CP: Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 68: 5706-5715, 2008.
102. 6-methylguanine-DNA methyltransferase gene. Cancer Res 56: 2029-2032, 1996.
103. 6- Methylguanine-DNA methyltransferase regulation by p53 in astrocytic cells. Cancer Res 67: 580-584, 2007.
104. Dinca EB, Lu KV, Sarkaria JN, Pieper RO, Prados MD, Haas-Kogan DA, Vandenberg SR, Berger MS and James CD: p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. Cancer Res 68: 10034-10039, 2008.
105. Batista LF, Roos WP, Christmann M, Menck CF and Kaina B: Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks. Cancer Res 67: 11886-11895, 2007.